Hepatic expression of adiponectin receptors increases with non-alcoholic fatty liver disease progression in morbid obesity in correlation with glutathione peroxidase 1.
BACKGROUND
The prevalence of non-alcoholic fatty liver disease (NAFLD) in obesity is very high. The role of adiponectin receptors in NAFLD progression remains still unclear. We speculate that changes in the hepatic expression levels of the two adiponectin receptors may be associated with the expression of oxidative stress-related genes.


METHODS
We studied 60 morbidly obese patients with NAFLD, who underwent liver biopsy at the time of bariatric surgery. We measured the hepatic messenger-RNA concentration of adiponectin receptors (ADIPOR1 and ADIPOR2), glutathione peroxidase 1 (GPx1), glutathione reductase (GRd) and inducible oxide nitric synthase. Additionally, biochemical parameters and oxidative stress markers were determined in blood samples. According to the Kleiner score, the patients were divided into two groups: group 1 (25 patients without steatohepatitis) and group 2 (25 patients with probable steatohepatitis and ten patients with steatohepatitis).


RESULTS
The messenger-RNA concentration of all genes analysed in the study was higher among the patients in group 2. However, no differences in blood oxidative stress markers were observed. Strong correlations were found among the expression levels of ADIPOR1, ADIPOR2 and GPx1. The multivariate analysis showed that the only independent variable associated with NAFLD progression was the increase in GPx1 expression levels.


CONCLUSIONS
NAFLD progression in morbid obesity is associated with increase in hepatic adiponectin receptor and oxidative stress-related genes. The linear correlations suggest that ADIPOR1, ADIPOR2 and GPx1 share key molecular factors in the regulation of the genetic expressions.
Research Unit, San Cecilio University Hospital, Av de Madrid s/n, 18012, Granada, Spain. angel_carazo@yahoo.es
Angel
A
Carazo
Josefa
J
León
Jorge
J
Casado
Ana
A
Gila
Sergio
S
Delgado
Ana
A
Martín
Laura
L
Sanjuan
Trinidad
T
Caballero
Jose Antonio
JA
Muñoz
Rosa
R
Quiles
Angeles
A
Ruiz-Extremera
Luis Miguel
LM
Alcázar
Javier
J
Salmerón
D000328:Adult; D015415:Biomarkers / Q000378:metabolism; D015331:Cohort Studies; D018450:Disease Progression; D005234:Fatty Liver / Q000209:etiology / Q000378:metabolism; D005260:Female; D005979:Glutathione Peroxidase / Q000235:genetics / Q000378:metabolism*; D005980:Glutathione Reductase / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D009573:Nitrites / Q000378:metabolism; D065626:Non-alcoholic Fatty Liver Disease; D009767:Obesity, Morbid / Q000150:complications / Q000378:metabolism*; D018384:Oxidative Stress / Q000502:physiology; D012333:RNA, Messenger / Q000378:metabolism; D054419:Receptors, Adiponectin / Q000235:genetics / Q000378:metabolism*; D000094765:Glutathione Peroxidase GPX1
C475418:ADIPOR1 protein, human; C475420:ADIPOR2 protein, human; D015415:Biomarkers; D009573:Nitrites; D012333:RNA, Messenger; D054419:Receptors, Adiponectin; D005979:Glutathione Peroxidase; D052247:Nitric Oxide Synthase Type II; D005980:Glutathione Reductase; D000094765:Glutathione Peroxidase GPX1; C000722067:GPX1 protein, human
Obes Surg. 2007 Feb;17(2):155-61
17476865
Hepatology. 2005 Jun;41(6):1313-21
15915461
Nature. 2003 Jun 12;423(6941):762-9
12802337
Gastroenterology. 1998 Apr;114(4):842-5
9547102
J Clin Invest. 2006 Jul;116(7):1784-92
16823476
Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10308-13
15210937
Biochem J. 2009 Jan 1;417(1):183-93
18752470
Obesity (Silver Spring). 2006 Jan;14(1):28-35
16493120
Curr Med Chem. 2009;16(19):2373-94
19601787
Biochem Biophys Res Commun. 2008 Sep 12;374(1):106-10
18602371
Cell Metab. 2009 Oct;10(4):260-72
19808019
Alcohol Clin Exp Res. 2010 Feb;34 Suppl 1:S18-24
18986378
Gut. 2005 Jan;54(1):117-21
15591515
Liver Int. 2009 Oct;29(9):1431-8
19422483
Metabolism. 2007 Nov;56(11):1478-85
17950097
Science. 2004 Oct 15;306(5695):457-61
15486293
Metabolism. 2006 Mar;55(3):396-401
16483885
Nat Med. 2007 Mar;13(3):332-9
17268472
Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8852-7
15184668
FEBS J. 2010 May;277(10):2304-17
20423458
J Clin Gastroenterol. 2005 Mar;39(3):237-42
15718867
Hepatology. 2010 Feb;51(2):679-89
20041406
Eur J Immunol. 2010 Mar;40(3):616-9
20201014
Nature. 2010 Apr 29;464(7293):1313-9
20357764
Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1079-86
17164441
J Hepatol. 2006 Oct;45(4):600-6
16899321
J Clin Endocrinol Metab. 1999 May;84(5):1513-7
10323371
Hepatology. 2009 Sep;50(3):957-69
19585655
Proc Natl Acad Sci U S A. 2009 May 26;106(21):8665-70
19433800
Int J Obes (Lond). 2010 May;34(5):846-51
20125105
Clin Biochem. 2010 Jul;43(10-11):815-21
20398645
Hepatol Res. 2009 Oct;39(10):963-71
19624767
World J Gastroenterol. 2008 Jan 14;14(2):193-9
18186554
Obesity (Silver Spring). 2006 Dec;14(12):2145-53
17189540
J Gastroenterol Hepatol. 2009 Feb;24(2):233-7
18713296
J Gastroenterol. 2007 Nov;42(11):897-903
18008034
J Biol Chem. 1997 Jun 27;272(26):16644-51
9195979
Obes Surg. 2009 Apr;19(4):467-74
18923878
Trends Endocrinol Metab. 2008 Dec;19(10):371-9
18929493
PLoS One. 2007 Sep 19;2(9):e898
17878933
J Nutr. 1998 Jul;128(7):1070-6
9649587